Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page
- Check3 days agoChange DetectedRevision updated to v3.0.2; Back to Top element removed. Core content and key data remain unchanged.SummaryDifference0.5%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.5%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. These changes enhance the clarity and relevance of the page's content.SummaryDifference76%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.SummaryDifference4%
Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.